Compare AbbVie Inc (ABBV) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? AbbVie Inc trades at $253.6 (market cap $449.91B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.14. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none. Which is the better fit depends on your goals.
| ABBV | VWO | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $61.24 |
52-Week Low | $184.85 | $49.54 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
VWO (Vanguard FTSE Emerging Markets ETF) trades at $60.07, up 1.74% on the day, with a bullish technical signal from moving averages. The ETF maintains a low 0.06% expense ratio and a 2.4% dividend yield, positioning it as a cost-efficient emerging markets vehicle. Recent news highlights performance comparisons with competing funds and the impact of South Korea's exclusion from its index, which has contributed to underperformance relative to some peers year-to-date.
The outlook for VWO hinges on broad emerging market growth and its low-cost advantage, but faces risks from geopolitical tensions, index methodology excluding South Korea, and potential underperformance versus developed market funds. The ETF offers diversification but may lag during periods of US market strength or when specific excluded markets outperform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
